Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q1 FY2026 Earnings Presentation
36 slides from Healthcare Global Enterprises's earnings presentation, Aug 1, 2025
Slide 1: Exchange cover letter: Investor Presentation
August 01, 2025 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam, S
Slide 2: Healthcare Global Enterprises Limited Investor Presentation August 2025
HEALTHCARE GLOBAL ENTERPRISES LIMITED I NV E STOR P R E SE NTA TI ON August 2025
Slide 3: Safe Harbor
SAFE HARBOR This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Largest Pan-India Oncology Hospital Chain
Largest Pan-India Oncology Hospital Chain LARGEST GEOGRAPHICAL REACH… 2 Center of Excellence (CoE) 10 19 ~55% 22 Cancer Care Centers 1 Number of Number of Addressable market3 4* Multi-specialty hospitals states covered5 cities covered5 (population) 6 Day care centers 25 16/18 3.7L+ Jaipur No. of cen
Slide 5: Redefining Cancer Care in India
Redefining Cancer Care in India Largest oncology focused Strong commercial engine driving hospital chain with 1 5 digital and brand transformation a pan India network Focused factory approach and Successful playbook of smart Tumor board, pioneered by Dr. Ajai, 2 6 acquisitions and driving sustained
Slide 6: Industry Opportunity
Industry Opportunity LARGE AND GROWING ONCOLOGY MARKET IN INDIA INDIA IS A SIGNIFICANTLY UNDER-COVERED CANCER INDUSTRY INRbn Population coverage by cancer registries1 CAGR 13-14% CAGR 12% 263 3% 97% 1% 89% 3% 3% 151 1% 41% 10% 2019 Population Cancer Relapse Affordability Realization 2024 2030E growt
Slide 7: Low early-stage diagnosis and skewness of CCC towards metros are key problems
Low early-stage diagnosis and skewness of CCC towards metros are key problems LOW EARLY-STAGE DIAGNOSIS IN INDIA… … LEADING TO HIGH MORTALITY TO INCIDENCE RATIO 81% 88% 91% 71% 73% 70% 61% 51% 52% 56% 29% 31% 30% 31% 26% 25% 28% 33% 19% 17% 22% 23% 15% 8% Breast Cancer Head and Neck Lung Cancer Brea
Slide 8: Global case studies reinforce the need for single specialty cancer hospitals
Global case studies and research reinforces the need to create single specialty hospitals for cancer care Objective of independently focusing on cancer Announced collaboration with Beth Israel Terminated partnership with Brigham and care rather than operating within a large health Deaconess Me
Slide 9: HCG positioned as Destination for Cancer Care
HCG has positioned itself as ‘Destination for Cancer Care’ with superior clinical and non-clinical expertise… DIAGNOSTICS TREATMENT POST CARE Genomics and Digital PET Preventive Oncology Medical Oncology Radiation Oncology Surgical Molecular Imaging Psychological Preventive Oncology Molecular and Ha
Slide 10: Underpinned by state-of-the-art technological expertise
…Underpinned by state-of-the-art technological expertise TRACK RECORD OF BEING 1st TO LAUNCH State-of-the-art Equipment in each modality Diagnostics ADVANCED TECHNOLOGY IN INDIA 19 Total PET AI-based 2022 CTs RIS PACS Digital PET CT Digital Digital Tomosynthesis Skyra Tesla Molecular / Ethos / Patho
Slide 11: Tumor Board approach
“ T u m o r B o a r d a p p r o a c h” – P ione e r in s c ie nt if ic d is c ou rse -le d in n o v a t ion w it h r ig h t c a s e s e le c t io n a n d le a r n in g me t h o d o lo g y Spearheaded by Dr. Ajai, who also heads 17+ years of nation wide, Supplemented by multiple IRC1 of 30+ oncologis
Slide 12: Case Study: Better clinical outcomes vs leading international peers
Case Study:HCG has been able to achieve better clinical outcomes compared to leading int’l cancer focused peers owing to its focused approach TREATMENT ADMINISTERED AND OUTCOMES – HCG VS. MD ANDERSON COVERAGE BY HARVARD OUTCOME: 5-YEAR SURVIVAL GLOBALLY COMPARABLE OUTCOMES N=729 N=2,451 TNBC Non-TNB
Slide 13: Case Study: Leveraging Genomics to drive better outcomes
Case Study : Leveraging “Genomics” to drive better outcomes 1st in Asia to complete 120+ clinical runs (1k+ patients) 1,000+ 1,735+ of Comprehensive Genomic Profiling Patient samples processed Total number of genomic with TSO500 alterations detected in cohort PRECISION Give the right diagnosis at th
Slide 14: HCG has successfully decoded the oncology business model across metros and non-metros
HC G ha s s u c c essf u lly d e c o d e d t h e o n c o lo g y b u s in e ss mo d e l r e s u lt in g in r o b u s t p e r f or man ce a c r o ss b o t h me t r o s & n o n -me t r os 10 NON-METRO CENTERS WITH 15%+ ROCE STRONG PERFORMANCE ACROSS METROS AND NON-METROS Key Parameters Metros Non-metro
Slide 15: Geographic Presence
Established market leading positions across 16 of 18 cities HCG COMMANDS MARKET LEADERSHIP IN ~90% OF METROS & NON-METROS THE CITIES IT IS PRESENT IN2 # of cancer 12 4 2 centers : 211,2 Geographic Presence MULTIPLE METROS # of cancer centers : 8 2 2 4 Peer 1 # of cancer centers : 14 Peer 2 1 2 <5 CI
Slide 16: Driving higher growth in market leading centers
Driving higher growth in market leading centers Centre of Excellence Upcoming Centre of Excellence Premier non-metro center KR HCC Cuttack Revenue FY18 FY20 FY25 FY18 FY20 FY25 FY18 FY20 FY25 Engaged seasoned Regional Head Strong Doctor Partner alignment Strong Doctor Partner alignment Stren
Slide 17: Significant focus on turnaround and profitability of key centers
Significant focus on turnaround and profitability of key centers Nagpur Jaipur Borivali Revenue FY20 FY25 FY20 FY25 FY20 FY25 EBITDA (IND AS) FY20 FY25 FY20 FY25 FY20 FY25 Improving mix of clinical strength across modalities Engaged COO with proven track record New regional head appointed in O
Slide 18: Articulating HCG's RoCE journey till date
Articulating HCG’s RoCE journey till date ESTABLISHED CENTERS EMERGING CENTERS HCG(1) Consistent growth in established Market leadership Acquired / established in recent years centers Track record of consistent profitability Substantial investment outlay recently Key metros scaled up 18 CCCs + 6 Day
Slide 19: Breakdown of FY25 ROCE
Breakdown of FY25 ROCE RoCE FOR KEY CENTERS (CONTRIBUTING OVERALL ROCE VIEW TO 75%+ EBITDA MARGINS) 32% 17% 25% 13% Established Overall Emerging 2% Yet to breakeven (18)% Bangalore Vintage 1 Vintage 2 Vintage 4 (> 8 years) (~ 5 years) (Nascent) Established centers already operate at a superior ROC
Slide 20: Digital Marketing - Journey So Far
Digital Marketing - JOURNEY SO FAR Digital Revenues as % of Topline Metro vs Non-Metro 10.2% 14.5% 867 Non-Metro 278 +67% 867 Metro 520 136 520 589 384 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 Source wise Digital Revenues Revenue from Digital Channels Q1FY25 Q1FY26 • Revenues from Digital Channels such as 0%
Slide 21: Q1 FY26 Financial & Operational Highlights
Q1 FY26 FINANCIAL & SUBASENI LENKA, CANCER WINNER OPERATIONAL HIGHLIGHTS I am eternally thankful to Dr. Panda and other specialists at HCG Panda Cancer Hospital, as the specialists were able to treat my condition the right way, the first time 20 w w w . h c g o n c o l o g y. c o m
Slide 22: Financial Highlights Q1FY26
Financial Highlights Q1FY26 Rs i n M n REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers +17% +17% +3% 6,132 5,982 144 149 5,256 5,112 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 ADJUSTED EBITDA PROFIT AFTER TAX PROFIT AFTER TAX ADJUSTED EBITDA* MARGIN* (Pre-IND AS) (Post-IND AS
Slide 23: Improved Performance Leading to Profitability
Improved Performance Leading to Profitability 1.7x 5,851 6,132 5,269 5,535 5,586 4,870 4,699 4,946 4,422 4,607 4,079 4,200 4,247 Revenue 3,646 (INR mn) Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 1.7x 1,042 1,070 1,118 864 941 929 923 EBITDA (Excl. 740 760 773
Slide 24: Growth Across HCG Centers
Growth Across HCG Centers Established Centers Emerging Centers ~1.3x g r o w t h i n l a s t 9 q u a r t e r s ~1.6x g r o w t h i n l a s t 9 q u a r t e r s REVENUE +16% +24% 5,264 5,396 587 587 4,637 4,848 4,931 530 519 4,085 4,290 4,117 4,330 446 475 403 417 358 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY2
Slide 25: Strong Operating Metrics with Significant Capacity Headroom
Strong Operating Metrics with Significant Capacity Headroom Key Driver Metric Indicator % Revenue Q1’25 Q4’25 Q1’26 +16.8% 167 143 Lead indicator of Volume Growth; key 116 OPD Footfall (‘000) operating metric tracked by HCG; has 19%* correlation to OPD Footfalls +20.3% 47 49 41 Key indicator for Med
Slide 26: HCG - Q1FY26 Operational Metrics
HCG – Q1FY26 Operational Metrics # ESTABLISHED CENTERS EMERGING CENTERS ESTABLISHED CENTERS TOTAL AOR (%) AOR (%) ROCE (%) A O R ^* ( % ) 67.1% 68.3% 53.7% 17.3% 66.9% in Q1FY25 51.2% in Q1FY25 18.4% in Q1FY25 65.6% in Q1FY25 140 bps 249 bps 110 bps 150 bps ROCE (Pre-IndAS) Operational beds increase
Slide 27: HCG - Cluster Wise Revenue Break Up
HCG – Cluster Wise Revenue Break Up C LU ST E R Q1FY26 Q1FY25 Y-o-Y K A R N ATA K A 1,640 1,563 5% • Karnataka : 5% growth due to fall in international patient inflow as a result of G U J A R AT 1,473 1,343 10% geopolitical headwinds and rationalization MAHARASHTRA 998 818 22% of lower realization p
Slide 28: Milann - Implementing Strategic Initiatives
Milann – Implementing Strategic Initiatives BENGALURU (5 Centers) Growth Shivananda Particulars Q1FY25 Q1FY26 Y-o-Y Indiranagar Whitefield New Registrations 1,360 1,519 12% JP Nagar HSR Emerging Centers IVF Cycles 355 300 -16% Established Centers (1) Revenues NORTH INDIA 144 149 3% (Rs. Mn.) Chandig
Slide 29: Capital Expenditure & Net Debt
Capital Expenditure & Net Debt CAPITAL EXPENDITURE (Rs. Mn.) NET DEBT (Rs. Mn.) NET DEBT 30 th June 2025 31 st Mar 2025 HCG CENTERS Q1FY25 Q1FY26 Bank Debt ( 1) 9,352 9,413 Vendor Finance ( 2) 180 288 Established Other Debt 114 113 786 912 Centers Less: Cash & Cash Equivalents ( 3) -2,415 -3,497 Eme
Slide 30: Q1 FY26 Consolidated Profit & Loss Account
Q1 FY26 Consolidated Profit & Loss Account Profit and Loss (in Rs. Mn.) Q1 FY26 Q1 FY25 Y-o-Y FY25 FY24 Y-o-Y Revenues from Operations 6,118.0 5,246.9 22,181.2 19,078.7 Income from Govt. Grant 13.6 8.9 47.1 42.5 Total Revenue from Operations 6,131.6 5,255.8 17% 22,228.3 19,121.2 16% Cost of Goods So
Slide 31: Historical Financial Highlights
HISTORICAL FINANCIAL SHANKAR, CANCER WINNER HIGHLIGHTS The days I was at HCG, I felt like I was sleeping at home. They never stop caring for you. The doctors and nurses are always finding ways to make this difficult journey as comfortable as possible 30 w w w . h c g o n c o l o g y. c o m
Slide 32: Historical Profit & Loss Account
Historical Profit & Loss Account Profit and Loss (in Rs. Mn.) FY25 FY24 FY23 FY22 FY21 FY20 CAGR Revenues from Operations 22,181 19,079 16,914 13,948 10,092 10,923 Income from Govt. Grant 47 43 30 30 43 33 Total Revenue from Operations 22,228 19,121 16,944 13,978 10,134 10,956 15% Costs of Goods Sol
Slide 33: Historical Balance Sheet - Equity & Liabilities
Historical Balance Sheet – Equity & Liabilities Balance Sheet - Equity & Liabilities (in Rs. Mn.) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Equity Share Capital 1,394 1,393 1,391 1,390 1,254 887 Other Equity 7,830 6,865 7,214 7,313 5,718 2,926 Equity Attributable To Equity Holders Of The 9,225 8,258
Slide 34: Historical Balance Sheet - Assets
Historical Balance Sheet - Assets Balance Sheet - Assets (in Rs. Mn.) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Non-Current Assets Property, Plant And Equipment 12,689 10,147 9,718 9,315 8,531 9,271 Capital Work in Progress 248 832 182 217 300 461 Rights-of-use Assets 6,941 4,907 3,813 4,045 4,114 5
Slide 35: Historical Cash Flow Statement
Historical Cash Flow Statement Cash Flow Statement (in Rs. Mn) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Net Profit Before Tax 570 677 449 878 -2,287 -1,193 Adjustments For: Non - Cash Items / Other Investment Or 3,685 2,914 2,753 1,666 3,619 2,988 Financial Items Operating Profit Before Working Cap
Slide 36: Thank You
THANK YOU Company: HealthCare Global Enterprises Limited Investor Relation Advisors: Strategic Growth Advisors CIN: L15200KA1998PLC023489 CIN: U74140MH2010PTC204285 For updates and specific queries, please visit Mr. Sagar Shroff / Mr. Ayush Haria www.hcgoncology.com sagar.shroff@sgapl.net / ayush.ha
HealthCare Global Enterprises — Q1 FY2026 Earnings Presentation on 6ix